IL6 and COVID-19: While transient, such alterations may enhance the risk of adverse cardiac events, particularly severe AVB, a complication which occurs in a nonnegligible proportion of COVID‐19 patients increasing short‐term mortality.6, 7, 8, 9 In this regard, our data provide further support to current anti‐inflammatory treatment strategies employed in severe COVID‐19, including glucocorticoids and anti‐IL‐6‐targeted therapies (tocilizumab, sarilumab), as they could at the same time control respiratory involvement and reduce the risk of life‐threatening cardiac complications,55 specifically advanced AVB.